Teriflunomide for multiple sclerosis

  • Protocol
  • Intervention

Authors


Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To explore the potential benefits of teriflunomide and expand the available DMT options, the effectiveness and safety of teriflunomide as mono- and combination therapy, versus placebo or approved DMTs (IFN-β, glatiramer acetate, natalizumab, mitoxantrone, fingolimod or cladribine) for modifying disease in patients with MS will be assessed.